St51011

Manufactured by R&D Systems

Sourced in Germany

The ST51011 is a laboratory equipment product designed for general use in research and development settings. It serves as a device for performing specific functions required in various scientific experiments and analyses. The core functionality of the ST51011 is to provide a tool for conducting relevant tasks, without further interpretation of its intended use or application.

Automatically generated - may contain errors

Lab products found in correlation

Dy406, by R&D Systems (2 mentions) Ab46048, by Abcam (1 mentions) Drg00, by R&D Systems (1 mentions) Ab46027, by Abcam (1 mentions) Ab173194, by Abcam (1 mentions) Ab119585, by Abcam (1 mentions) Ab102523, by Abcam (1 mentions) Ab105136, by Abcam (1 mentions) Ab102531, by Abcam (1 mentions) Ab102526, by Abcam (1 mentions)

4 protocols using st51011

Serum Biomarker Profiling via ELISA

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum concentrations of interleukin (IL) 6 (Abcam, United States, ab46027), interferon (IFN) γ (Abcam, United States, ab46048), interferon-inducible protein (IP) 10 (Abcam, United States, ab173194), interferon α 1 (Abcam, United States, ab213479), IL-10 (Abcamn United States, ab100549), and HMGB-1 (IBL, Germany, ST51011), and the serum receptor for advanced glycation end-product (sRAGE, R&D, United States, DRG00) were detected via commercial ELISA kits following the instructions provided by the manufacturers (detailed in Supplementary materials).

Xu W., Du J., Wei T.T., Chen L.Y., Yang X.X., Bo T., Liu H.Y., Xie M.Z., Zhao T.S., Yang J.L., Cui F., Chen W.W, & Lu Q.B. (2022). Alterations in bile acids as metabolic signatures in the patients with human adenovirus type 7 infection. Frontiers in Medicine, 9, 896409.

+ Open protocol

+ Expand

Quantifying Cytokine Secretion in Doxorubicin-Treated Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Supernatants of cells treated with 5 µM or 0.2 µM doxorubicin or left untreated were harvested after 48 hours, and HMGB1, IL-6, TGF-β and VEGF were quantified using ELISA (IBL International GmbH, Cat#ST51011 and R&D Systems, Cat#DY406, DY1679, DY493).

Di Lorenzo A., Bolli E., Ruiu R., Ferrauto G., Di Gregorio E., Avalle L., Savino A., Poggio P., Merighi I.F., Riccardo F., Brancaccio M., Quaglino E., Cavallo F, & Conti L. (2022). Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy. Oncoimmunology, 11(1), 2086752.

+ Open protocol

+ Expand

Quantitative Biomarker Profiling in Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Commercially available ELISA kits were used to measure the concentrations or activity of HMGB1 (Shino Test Corporation, ST51011), DCN (R&D Systems, DY143, DY1060), IL6 (R&D Systems, M6000B, D6050), TNF (R&D Systems, MTA00B, DTA00D), NFKB (Active Motif, 43,296), MPO (Abcam, ab105136), LDH (Abcam, ab102526), trypsin (Abcam, ab102531), CTSB (Abcam, ab119585), and AMY (Abcam, ab102523) in the indicated samples.

Liu J., Zhu S., Zeng L., Li J., Klionsky D.J., Kroemer G., Jiang J., Tang D, & Kang R. (2021). DCN released from ferroptotic cells ignites AGER-dependent immune responses. Autophagy, 18(9), 2036-2049.

+ Open protocol

+ Expand

Cytokine Profiling of Doxorubicin-Treated Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

The supernatants of cells treated with 5 µM or 0.2 µM doxorubicin or left untreated were harvested after 48 hours, and HMGB1, IL-6, TGF-b and VEGF were quanti ed using ELISA (IBL International GmbH, Cat#ST51011 and R&D Systems, Cat#DY406, DY1679, DY493).

Lorenzo A.D., Bolli E., Ruiu R., Ferrauto G., Gregorio E.D., Avalle L., Merighi I.F., Riccardo F., Quaglino E., Cavallo F., & Conti L. (2021). Toll-Like Receptor 2 Promotes Breast Cancer Progression and Resistance to Chemotherapy.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!